Drugs / dofequidar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004886 | Dec 1999 → Jun 2002 | cancer of unknown primary site | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dofequidar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004886 ↗ |
| Known as | dofequidar fumarate | “dofequidar fumarate” NCT00004886 ↗ |
| Modality | Small molecule | — CHEMBL65067 ↗ |
| Route | Oral | “patients receive MS-209 orally” NCT00004886 ↗ |